46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

diseases per page:

Showing 1 to 10 of 4,325 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04585711 (ClinicalTrials.gov)	July 2023	7/10/2020	Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis	Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis	Juvenile Idiopathic Arthritis;Rheumatoid Arthritis;Obesity	Drug: Etanercept Optimal dosing	Duke University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not yet recruiting	2 Years	65 Years	All	30	Phase 1	United States
2	NCT05274243 (ClinicalTrials.gov)	September 2022	1/3/2022	2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis	2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 2-HOBA;Other: Placebo	Vanderbilt University Medical Center	NULL	Not yet recruiting	18 Years	N/A	All	32	Phase 2	United States
3	NCT05267431 (ClinicalTrials.gov)	June 2022	14/2/2022	Outcomes of Biological Therapy on Rheumatoid Arthritis	Outcomes of Different Biological Therapy on Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Biological Drug	Sohag University	NULL	Not yet recruiting	18 Years	N/A	All	200		Egypt
4	NCT04269993 (ClinicalTrials.gov)	April 1, 2022	12/2/2020	Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis	Impact of Acute Cannabis Administration on Pain Symptomology and Inflammatory Markers Among Patients ...	Rheumatoid Arthritis;Psoriatic Arthritis	Drug: Cannabis: placebo and medium THC/medium CBD	Brown University	NULL	Not yet recruiting	18 Years	65 Years	All	76	Phase 2	NULL
5	NCT05166304 (ClinicalTrials.gov)	April 2022	8/12/2021	Rebamipide in Patients With Active Rheumatoid Arthritis	Rebamipide as an Adjunct to Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rebamipide;Drug: Placebo	October 6 University	NULL	Not yet recruiting	18 Years	60 Years	All	100	Phase 1/Phase 2	NULL
6	NCT05264025 (ClinicalTrials.gov)	April 2022	10/1/2022	Fexofenadine in Patients With Active Rheumatoid Arthritis	Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid	Rheumatoid Arthritis	Drug: Fexofenadine;Drug: Placebo	October 6 University	NULL	Not yet recruiting	18 Years	60 Years	All	80	Phase 1/Phase 2	NULL
7	NCT05246293 (ClinicalTrials.gov)	March 2, 2022	17/1/2022	Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.	Safety and Tolerability of Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial ...	Rheumatoid Arthritis;Interstitial Lung Disease	Drug: Tofacitinib	National Institute of Respiratory Diseases, Mexico	NULL	Not yet recruiting	18 Years	N/A	All	60	Phase 2	Mexico
8	NCT05246280 (ClinicalTrials.gov)	March 2, 2022	16/12/2021	Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFa Therapy Response in Moderate to Severe ...	Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFa Therapy Response in P ...	Rheumatoid Arthritis	Drug: TC99m-tilmanocept	Navidea Biopharmaceuticals	NULL	Recruiting	18 Years	N/A	All	523	Phase 3	United States
9	NCT05238896 (ClinicalTrials.gov)	March 1, 2022	4/1/2022	BARIcitinib Cognitive Emotional and Neural signaTuRE	BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)	Rheumatoid Arthritis	Drug: Baricitinib Oral Tablet [Olumiant];Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	18 Years	75 Years	All	80	Phase 4	France
10	NCT05236491 (ClinicalTrials.gov)	March 2022	10/2/2022	COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases	COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases	Rheumatoid Arthritis;Autoimmune Rheumatologic Disease;Systemic Lupus Erythematosus;Systemic Vasculit ...	Biological: COVID-19 vaccine	Paul R Fortin	Canadian Institutes of Health Research (CIHR)	Not yet recruiting	18 Years	N/A	All	287	Phase 2/Phase 3	NULL

First Previous1 2 3 4 5…433Next Last